Cargando…

Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): 10-Year Update

PURPOSE OF REVIEW: APS ACTION is an international research network created to design and conduct large-scale, multicenter research in persistently antiphospholipid antibody (aPL)–positive patients. Given the expanding research activities of the network in the last decade since its creation, the purp...

Descripción completa

Detalles Bibliográficos
Autores principales: Erkan, Doruk, Sciascia, Savino, Bertolaccini, Maria Laura, Cohen, Hannah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088198/
https://www.ncbi.nlm.nih.gov/pubmed/33932165
http://dx.doi.org/10.1007/s11926-021-01008-8
_version_ 1783686802470600704
author Erkan, Doruk
Sciascia, Savino
Bertolaccini, Maria Laura
Cohen, Hannah
author_facet Erkan, Doruk
Sciascia, Savino
Bertolaccini, Maria Laura
Cohen, Hannah
author_sort Erkan, Doruk
collection PubMed
description PURPOSE OF REVIEW: APS ACTION is an international research network created to design and conduct large-scale, multicenter research in persistently antiphospholipid antibody (aPL)–positive patients. Given the expanding research activities of the network in the last decade since its creation, the purpose of this article is to review the scientific contributions of APS ACTION as well as future directions. RECENT FINDINGS: APS ACTION has achieved increased international collaboration with internal and external investigators for outcome, interventional, and mechanistic antiphospholipid syndrome (APS) studies. This has been linked to substantial progress in Core laboratory work, which has demonstrated that laboratories can achieve good agreement in performance of aPL assays by use of the same reagents, analyzer type, and protocols. SUMMARY: APS ACTION will continue to identify gaps in the existing aPL/APS literature, design mechanistic studies to elucidate underlying mechanisms, and conduct prospective, large-scale clinical studies, all for the ultimate goal of early diagnosis and improved management of aPL-positive patients.
format Online
Article
Text
id pubmed-8088198
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-80881982021-05-03 Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): 10-Year Update Erkan, Doruk Sciascia, Savino Bertolaccini, Maria Laura Cohen, Hannah Curr Rheumatol Rep Antiphospholipid Syndrome (S Zuily, Section Editor) PURPOSE OF REVIEW: APS ACTION is an international research network created to design and conduct large-scale, multicenter research in persistently antiphospholipid antibody (aPL)–positive patients. Given the expanding research activities of the network in the last decade since its creation, the purpose of this article is to review the scientific contributions of APS ACTION as well as future directions. RECENT FINDINGS: APS ACTION has achieved increased international collaboration with internal and external investigators for outcome, interventional, and mechanistic antiphospholipid syndrome (APS) studies. This has been linked to substantial progress in Core laboratory work, which has demonstrated that laboratories can achieve good agreement in performance of aPL assays by use of the same reagents, analyzer type, and protocols. SUMMARY: APS ACTION will continue to identify gaps in the existing aPL/APS literature, design mechanistic studies to elucidate underlying mechanisms, and conduct prospective, large-scale clinical studies, all for the ultimate goal of early diagnosis and improved management of aPL-positive patients. Springer US 2021-05-01 2021 /pmc/articles/PMC8088198/ /pubmed/33932165 http://dx.doi.org/10.1007/s11926-021-01008-8 Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021, corrected publication 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Antiphospholipid Syndrome (S Zuily, Section Editor)
Erkan, Doruk
Sciascia, Savino
Bertolaccini, Maria Laura
Cohen, Hannah
Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): 10-Year Update
title Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): 10-Year Update
title_full Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): 10-Year Update
title_fullStr Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): 10-Year Update
title_full_unstemmed Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): 10-Year Update
title_short Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): 10-Year Update
title_sort antiphospholipid syndrome alliance for clinical trials and international networking (aps action): 10-year update
topic Antiphospholipid Syndrome (S Zuily, Section Editor)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088198/
https://www.ncbi.nlm.nih.gov/pubmed/33932165
http://dx.doi.org/10.1007/s11926-021-01008-8
work_keys_str_mv AT erkandoruk antiphospholipidsyndromeallianceforclinicaltrialsandinternationalnetworkingapsaction10yearupdate
AT sciasciasavino antiphospholipidsyndromeallianceforclinicaltrialsandinternationalnetworkingapsaction10yearupdate
AT bertolaccinimarialaura antiphospholipidsyndromeallianceforclinicaltrialsandinternationalnetworkingapsaction10yearupdate
AT cohenhannah antiphospholipidsyndromeallianceforclinicaltrialsandinternationalnetworkingapsaction10yearupdate
AT antiphospholipidsyndromeallianceforclinicaltrialsandinternationalnetworkingapsaction10yearupdate